77278-34-3

Usage

Uses

Used in Pharmaceutical Industry:
1-Cyclopropylpiperazine-4-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of pharmaceuticals for its potential pharmacological properties. It plays a crucial role in the development of new drugs and medicines.
Used in Agrochemical Industry:
1-Cyclopropylpiperazine-4-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective and safe products for agricultural applications.
Used in Organic Synthesis:
1-Cyclopropylpiperazine-4-carboxylic acid tert-butyl ester is used as a valuable compound in organic synthesis reactions due to its stability and protective properties provided by the tert-butyl ester group. This makes it suitable for various chemical reactions and the synthesis of different bioactive molecules.

Upstream product

• 84098-43-1 trimethylsilyl ether of 1-methoxycyclopropanol 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 411235-57-9 cyclopropylboronic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 20327-23-5 1-cyclopropylpiperazine 
• 27374-25-0 [(1-Ethoxycyclopropyl)oxy]trimethylsilane 

Downstream Products

• 929622-21-9 4-(4-cyclopropyl-piperazine-1-carbonyl)-benzaldehyde 
• 929622-11-7 (4-cyclopropylpiperazin-1-yl)(4-((4-fluoropiperidin-1-yl)methyl)phenyl)methanone 
• 929622-08-2 Bavisant 
• 20327-23-5 1-cyclopropylpiperazine 
• 223556-29-4 1-cyclopropylpiperazine hydrochloride 

Relevant academic research and scientific papers

AMINOPYRIMIDINE HETEROCYCLIC COMPOUND WITH ADENOSINE RECEPTOR ANTAGONISTIC ACTIVITY

Disclosed hereinis an aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity, comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof. The aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activitydisclosed herein can be used as an effective adenosine receptor antagonist, and can be used for the treatment or prevention of disorders caused by abnormal level of adenosine.

Novel benzamide-based histamine H3 receptor antagonists: The identification of two candidates for clinical development

The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H3 receptor antagonists is described. The compounds described are high affinity histamine H3 antagonists. Optimization of the physical properties of these histamine H3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.

Copper-promoted N-cyclopropylation of anilines and amines by cyclopropylboronic acid

Reaction of anilines, primary and secondary aliphatic amines with cyclopropylboronic acid in dichloroethane in the presence of Cu(OAc)2 (1 equiv.), 2,2′-bipyridine (1 equiv.) and sodium carbonate or sodium bicarbonate (2 equiv.) under air atmos

AURORA KINASE INHIBITORS

Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein.

NOVEL COMPOUNDS

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR

Certain substituted benzamide compounds are histamine H3receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.

CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR

Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.

PYRAZOLE DERIVATIVES

A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES

The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.

NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES

The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.